Novo Nordisk's oral semaglutide enters late-stage trials, threatening Eli Lilly's obesity lead. Phase 3 data later this year will decide which company wins the pill race.
Novo Nordisk is testing an oral version of semaglutide, the drug behind Wegovy, in late-stage clinical trials. The once-daily pill, if approved, would let patients avoid injections, a hurdle that keeps many from starting or staying on GLP-1 therapy. The company reported positive Phase 2 data. It has not disclosed a timeline for regulatory submission. Analysts expect pivotal data later this year.
Eli Lilly (LLY) is not standing still. Lilly's tirzepatide, sold as Mounjaro and Zepbound, has shown stronger weight loss than semaglutide in head-to-head trials. Lilly also has its own oral GLP-1 candidate, orforglipron, in Phase 3 development. The two companies are racing to capture the oral segment. That segment could double the addressable market by making treatment more accessible.
For Novo, an oral pill would ease manufacturing bottlenecks. Wegovy and Ozempic require sterile filling lines and complex injection devices. A pill avoids those constraints. It lets Novo serve more patients without the capacity problems that have limited supply.
The risk is that the oral pill fails to match the injectable's efficacy or tolerability in larger trials. Nausea and vomiting were already issues with the injection. A different formulation could worsen those side effects. If the pill disappoints, Lilly's oral candidate would have a clearer path.
AlphaScala's proprietary model gives Novo Nordisk (NVO) a score of 58 out of 100, labeled Moderate. That reflects the binary risk-reward. Success could unlock substantial revenue. Trial outcomes are uncertain. The stock has returned roughly 12% since November. The Phase 3 readout will determine whether that momentum holds.
Amgen and Pfizer also have oral GLP-1 drugs in development. Novo and Lilly are the clear leaders. The oral pill battle is the next chapter. Lilly's market cap has surged past $800 billion on the strength of its obesity portfolio. An oral pill from Novo would not eliminate Lilly's advantage. It would close the gap. The Phase 3 data will decide which company has the stronger case.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.